Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross‐links: a longitudinal and cross‐sectional study

Hassager, Christian; Colwell, A.; Assiri, Adel M. A.; Eastell, Richard; Russell, R. G. G.; Christiansen, Claus

doi:10.1111/j.1365-2265.1992.tb02282.x

Cited by 68 publications

(22 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The advantages of these biochemical measures are that they are more acceptable to patients and allow repeated measures to be made. As bone markers have been shown to respond rapidly to interventions known to affect bone metabolism (hormone replacement therapy (Hassager et al, 1992), Vitamin D supplements (Gram et al, 1991) and, most recently, insulin-like Growth Factor 1 (Grinspoon et al, 1996)) they have a potentially important role in assessing both the mechanism of the abnormal bone turnover in anorexia and the ef®cacy of potential treatments.…”

Section: Measurement Of Bone Turnovermentioning

confidence: 99%

Osteoporosis—a serious health risk in chronic anorexia nervosa

Serpell

Treasure

1997

Eur. Eat. Disorders Rev.

View full text Add to dashboard Cite

Section: Measurement Of Bone Turnovermentioning

confidence: 99%

Osteoporosis—a serious health risk in chronic anorexia nervosa

Serpell

Treasure

1997

Eur. Eat. Disorders Rev.

View full text Add to dashboard Cite

“…The 24 active tablets contain 17p-estradiol in a daily dose of 1.5 mg. To prevent unopposed estrogen stimulation of the endometrium, the progestogen desogestrel has been added during the last 12 days of the 24-day estrogen period, in a dose of 150 ug per day. Details about the pharmacology, efficacy, acceptability and safety of Liseta'" can be found elsewhere (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20).…”

Section: Introductionmentioning

confidence: 99%

Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette® and Liseta®

Timmer¹,

Srivastava

Dieben³

et al. 1999

Eur. J. Drug Metab. Pharmacokinet.

View full text Add to dashboard Cite

In a three-period cross-over study with 24 healthy young females (study part 1), the bioavailability of etonogestrel (3-ketodesogestrel) was determined after a single oral dose of two Cerazette tablets (each containing 75 microg desogestrel), one Liseta tablet (containing 150 microg desogestrel and 1.5 mg 17beta-estradiol), and an intravenous dose of 150 microg etonogestrel. Etonogestrel serum levels from 23 subjects could be analysed by radio-immunoassay. The geometric mean bioavailability of etonogestrel from Cerazette and Liseta tablets was 0.79 and 0.82, with 95% confidence intervals of 0.73-0.86 and 0.76-0.88, respectively. Also, the oral formulations were found to be bioequivalent. Subsequently, the single-dose pharmacokinetic parameters of etonogestrel from Cerazette tablets were compared with those after multiple dosing of one Cerazette tablet once daily for 7 days, in a subgroup of 12 subjects (study part 2). A steady state was observed from the fourth day of daily dosing onwards, with time-invariant parameters except for a 14% lower dose-normalised AUC. The least-squares geometric means of the elimination half-life of etonogestrel were approximately 30 h for the three single-dose treatments in study part 1, as well as for the single- and multiple-dose treatments of Cerazette in study part 2, without differences between groups.

show abstract

“…In postmenopausal osteoporosis, bone turnover, measured by biochemical markers, increases an average of 2-3 standard deviations above mean premenopausal levels 55,56 . Changes in microarchitecture, mineralization, bone density, and bone strength are linked to bone turnover.…”

Section: Skeletal Effects Of Reduced Bone Turnovermentioning

confidence: 99%

Bone safety of long-term bisphosphonate treatment

Rodan

Reszka

Golub

et al. 2004

Current Medical Research and Opinion

112

View full text Add to dashboard Cite

Bisphosphonates (BPs) are widely used in osteoporosis and other bone diseases. Treatment of osteoporosis would, in many instances, involve continued use of BP for a number of years, so it is pertinent to examine skeletal consequences of long-term BP use. Through a non-systematic review of the literature, this commentary considers the reduction in bone turnover and retention in the skeleton with regard to the long-term safety of BP use. BPs normalize bone turnover rates within weeks and no further suppression is seen during long term use, documented up to 10 years. This indicates that the BP retained in bone does not augment or contribute to the pharmacological activity of newly administered BP. Therefore, pharmacologically, long term treatment is not different from short term treatment. Multiple studies have shown that reductions in bone turnover are associated with increased bone density, more homogeneous mineralization, and reduced fracture risk. The amount of BP retained in bone after 10 years of alendronate treatment was estimated at 75 mg per 2 kg mineral, using a pharmacokinetic model for a dose of 10 mg per day. This small fraction, which is unevenly distributed between cancellous and cortical bone, seems unlikely to change bone mechanical properties. Taken together, the known mechanism of action of potent BPs and the experience accrued from treating a large number of patients, including up to 10 years follow-up in controlled trials, have identified only beneficial BP effects on bone.

show abstract

Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross‐links: a longitudinal and cross‐sectional study

Abstract: Urinary pyridinoline and deoxypyridinoline, new markers of bone resorption, remain fairly constant in the years before the menopause and start to increase about 6 months after the last menstrual bleeding. This increase is reversed by hormone replacement therapy.

Cited by 68 publications

References 18 publications

Osteoporosis—a serious health risk in chronic anorexia nervosa

Osteoporosis—a serious health risk in chronic anorexia nervosa

Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette® and Liseta®

Bone safety of long-term bisphosphonate treatment

Contact Info

Product

Resources

About